CCA balance sheet
Dependency, TTNS
A descriptive comparison of the costs and outcomes (clinical and economic) of the ELECTRIC trial is presented in the cost-consequence balance sheet (Table 
Descriptive cost consequence analysis balance sheet for the ELECTRIC trial• In contrast to usual continence care which seeks to contain UI, TTNS is a treatment seeking to attempt to address the cause of UI. It is non-invasive, acceptable to Care Home resident and tolerated well.• Staff time to set up/take off the machine was 5 min or less for 94% of stimulations.• Staff do not require to be present for the duration of treatment.• No impact on absorbent product use. Average cost of £1.19 (SD £1.51) per participant in 24 h, during trial. [Mean difference (SD) between TTNS and Sham at 18 weeks: number of pads per day, 0.13 (-0.160, 0.416); value of pads (£), -1.16 (-0.400, 0.492)].• No evidence of impact on health-related quality of life (as measured using DEMQOL-U/DEMQOL-Proxy-U). [Mean difference (SD) between TTNS and Sham at 18 weeks: DEMQOL-U, -0.042 (-0.119, 0.034); DEMQOL-Proxy-U, -0.002 (-0.031, 0.027)].• No impact on resources (staff time, equipment) required for residents’ toilet assistance. Dependency on staff for toilet assistance was indicative of labour intensity of continence care. [Estimated value of staff time (£) per 24-hour period, assuming 5 min per visit: TTNS, 19.17 (SD 13.22); Sham 17.30 (SD 13.33)].• Additional cost per resident to receive TTNS (cost of machine and electrodes) during the trial was estimated as £81.20. This proportional cost would lower with active reuse of electrodes and would change further depending on both the lifetime of the machine and also the number of residents that might be expected to use the machine. Cost of staff training and support during the trial was estimated as £121.03 per staff member.